Showing results (61-70 of 186) with videos related to

Sort By:
Pageof 19
Leukemia & Lymphoma|November 28, 2017
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendationsMartin Dreyling, Igor Aurer, Sergio Cortelazzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2012
Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptorsCarlo Visco, Francesco Maura, Giacomo Tuana, et al.
BMC Cancer|August 25, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentStephanie Herold, Christian Schmidt, Carlo Visco, et al.
British Journal of Haematology|June 28, 2024
Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana LinfomiFederica Cavallo, Michele Clerico, Elisa Lucchini, et al.
Clinical Chemistry and Laboratory Medicine|December 30, 2025
Flow cytometry, cytology and histology in the diagnosis of ocular hematologic neoplasms: a 15-year monocentric experience with a focus on ocular lymphomasAlessandra Falda, Veronica Davanzo, Dario Marino, et al.
Annals of Hematology|April 17, 2024
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life surveyAndrea Duminuco, Alessandra Romano, Isacco Ferrarini, et al.
Cancers|January 21, 2022
High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma PatientsDario Marino, Marco Pizzi, Iuliia Kotova, et al.
Hematological Oncology|April 30, 2022
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paperSarah Bailly, Guillaume Cartron, Sridhar Chaganti, et al.
Journal for Immunotherapy of Cancer|July 17, 2021
Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cellsAnna Dalla Pietà, Elisa Cappuzzello, Pierangela Palmerini, et al.
British Journal of Haematology|December 8, 2011
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio LinfomiFrancesco Merli, Stefano Luminari, Fiorella Ilariucci, et al.
Pageof 19